# First-Line Treatment for Advanced Non-squamous Non-Small-Cell Lung Cancer With Negative Driver Gene: a Single-center, Single-Arm Trial

> **NCT05648071** · PHASE3 · UNKNOWN · sponsor: **Qianfoshan Hospital** · enrollment: 60 (estimated)

## Conditions studied

- Advanced Non-squamous Non-Small-Cell Lung Cancer

## Interventions

- **DRUG:** Sintilimab

## Key facts

- **NCT ID:** NCT05648071
- **Lead sponsor:** Qianfoshan Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-12-01
- **Primary completion:** 2024-12-01
- **Final completion:** 2025-07-01
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2022-12-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05648071

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05648071, "First-Line Treatment for Advanced Non-squamous Non-Small-Cell Lung Cancer With Negative Driver Gene: a Single-center, Single-Arm Trial". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT05648071. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*